Flagship Pioneering Appoints Travis Wilson as Growth Partner

CAMBRIDGE, Mass., September 17, 2024 – Flagship Pioneering, the bioplatform innovation company, announced today that Travis Wilson, a seasoned leader in growth equity and venture investing for biopharma, joined as Growth Partner. In this role, Wilson will help grow and scale several companies within Flagship’s ecosystem, working primarily with leadership teams from later-stage companies or Growth Companies (GrowthCos) on long-term value creation strategy, financing, business development, partnerships, and organizational development. 

Wilson brings more than 20 years of experience and leadership in growth equity, public and private financing, pharmaceutical partnerships, mergers and acquisitions, and company creation. He joins Flagship from Gurnet Point Capital, a life sciences private equity fund focused on public market buyouts, where he served as Managing Partner. He was previously the President and CEO of Stealth BioTherapeutics (NASDAQ: MITO), a mitochondrial focused company developing a therapeutic platform to treat common and rare diseases. While CEO of Stealth Biotherapeutics, and for more than a decade, he was a member of the life sciences investment team for Morningside, a global venture and private equity firm. Wilson has also served as a board director for nonclinical, late-stage clinical, and commercial life sciences companies, providing operational and management support across a broad spectrum of therapeutic areas, including orphan diseases, oncology, immunology, cardio-renal disorders, neurology, and ophthalmology.

“Travis is a welcome addition to our team of leaders focused on growing and scaling our later-stage companies, or GrowthCos,” said Noubar Afeyan, Ph.D., Founder and CEO of Flagship Pioneering. “Travis’ extensive experience driving organizational growth, coupled with his expertise in corporate strategy, finance, and business development, has already made an impact as we steward our companies toward long-term value creation.”

“I am pleased to join Flagship’s leadership team and to leverage my experience in scaling biotech and pharma companies to accelerate the pioneering technology and innovative bioplatforms that underlie Flagship’s ecosystem of companies,” said Travis Wilson, Growth Partner, Flagship Pioneering.

About Travis Wilson

Travis Wilson comes to Flagship with more than 20 years of life sciences investing and executive experience. Prior to joining Flagship, he was the Managing Partner of Gurnet Point Capital, a life sciences private equity fund focused on public market buyouts, including the privatization of commercial biotechnology companies such as Radius Health (NASDAQ: RDUS), Paratek (NASDAQ: PRTK), and Corium (NASDAQ: CORI).

Wilson was previously the President and CEO of Stealth BioTherapeutics (NASDAQ: MITO), a mitochondrial focused company developing a therapeutic platform to treat common and rare diseases. While CEO of Stealth Biotherapeutics, and for more than a decade, he was a member of the life sciences investment team for Morningside, a global venture and private equity firm. As an investor with Morningside, Wilson was involved in several successful deals, including BioVex (acquired by Amgen), Aduro (merged with Chinook Therapeutics, NASDAQ: KDNY), Liquidia (NASDAQ: LQDA), Apellis (NASDAQ: APLS), and ACD (acquired by Bio-Techne).

Wilson has also served as a board director for nonclinical, late-stage clinical, and commercial life sciences companies, providing operational and management support across a broad spectrum of therapeutic areas, including orphan diseases, oncology, immunology, cardio-renal disorders, neurology, and ophthalmology. He has regularly spoken on life sciences investing and portfolio management, and is a long-time supporter of patient-advocacy groups including the American Cancer Society, United Mitochondrial Disease Foundation, and National Organization for Rare Disorders.

He received degrees in Chemical Engineering and Law, both from the University of Wisconsin.

About Flagship Pioneering

Flagship Pioneering invents and builds bioplatform companies, each with the potential for multiple products that transform human health or sustainability. Since its launch in 2000, Flagship has originated and fostered more than 100 scientific ventures, resulting in more than $75 billion in aggregate value. To date, Flagship has deployed over $3.8 billion in capital toward the founding and growth of its pioneering companies alongside more than $27 billion of follow-on investments from other institutions. The current Flagship ecosystem comprises 40 companies, including Foghorn Therapeutics (NASDAQ: FHTX), Moderna (NASDAQ: MRNA), Omega Therapeutics (NASDAQ: OMGA), Sana Biotechnology (NASDAQ: SANA), Generate Biomedicines, Inari, Indigo Agriculture, and Tessera Therapeutics.